State Street’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

State Street’s Portfolio NKGN Stock Details NKGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11,200	Closed	-$7.34K	–	4322
2024 Q4	$7.34K	Hold	11,200	–	–	﹤0.01%	4289
2024 Q3	$4.23K	Hold	11,200	–	–	﹤0.01%	4282
2024 Q2	$14.2K	Buy	+11,200	New	+$15.6K	﹤0.01%	4307

Other funds holding NKGN

Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

UOC

University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

State Street's NKGN Position: Q1 2025 in Review

State Street sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q1 2025, closing a stake of 11,200 shares — an estimated $7.34K sold.

State Street first reported a position in NKGN in Q2 2024 and held it in 3 quarters. The position peaked at $14.2K in Q2 2024. 3 funds tracked by Wall St. Rank hold NKGN as of Q1 2025.

State Street reported no remaining NKGen Biotech, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
State Street sold 11,200 NKGen Biotech, Inc. Common Stock shares in Q1 2025, an estimated $7.34K.
State Street first reported a position in NKGen Biotech, Inc. Common Stock in Q2 2024 and held it in 3 quarters.
State Street's NKGen Biotech, Inc. Common Stock position peaked at $14.2K in Q2 2024.
3 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2025.

Based on State Street's 13F filing for Q1 2025, filed 15 May 2025.